JAMA (Journal of the American Medical Association)
前往频道在 Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
显示更多📈 Telegram 频道 JAMA (Journal of the American Medical Association) 的分析概览
频道 JAMA (Journal of the American Medical Association) (@jamaupdates) 英语 语言赛道中的 是活跃参与者。目前社区聚集了 16 560 名订阅者，在 医学 类别中位列第 1 466，并在 美国 地区排名第 2 239 位。
📊 受众指标与增长动态
自 невідомо 创建以来，项目保持高速增长，吸引了 16 560 名订阅者。
根据 06 十月, 2026 的最新数据，频道保持稳定运转。过去 30 天订阅人数变化为 288，过去 24 小时变化为 17，整体触达仍然可观。
- 认证状态： 未认证
- 互动率 (ER)： 平均受众互动率为 4.02%。内容发布后 24 小时内通常能获得 1.91% 的反应，占订阅者总量。
- 帖子覆盖： 每篇帖子平均可获得 666 次浏览，首日通常累积 316 次浏览。
- 互动与反馈： 受众积极参与，单帖平均反应数为 1。
- 主题关注点： 内容集中在 patient, disease, treatment, drug, guideline 等核心主题上。
📝 描述与内容策略
作者将该频道定位为表达主观观点的平台：
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
凭借高频更新（最新数据采集于 07 十月, 2026），频道始终保持新鲜度与高覆盖。分析显示受众积极互动，使其成为 医学 类别中的关键影响点。
16 560
订阅者
+1724 小时
+667 天
+28830 天
数据加载中...
相似频道
标签云
进出提及
---
---
---
---
---
---
吸引订阅者
十月 '2610月 '26
十月 '26
+50
在0个频道中
九月 '26
+301
在0个频道中
Get PRO
八月 '26
+361
在0个频道中
Get PRO
七月 '26
+440
在0个频道中
Get PRO
六月 '26
+422
在0个频道中
Get PRO
五月 '26
+584
在0个频道中
Get PRO
四月 '26
+437
在0个频道中
Get PRO
三月 '26
+217
在0个频道中
Get PRO
二月 '26
+247
在0个频道中
Get PRO
一月 '26
+321
在0个频道中
Get PRO
十二月 '25
+277
在0个频道中
Get PRO
十一月 '25
+366
在2个频道中
Get PRO
十月 '25
+164
在0个频道中
Get PRO
九月 '25
+12
在0个频道中
Get PRO
八月 '25
+29
在0个频道中
Get PRO
七月 '25
+30
在0个频道中
Get PRO
六月 '25
+17
在0个频道中
Get PRO
五月 '25
+9
在0个频道中
Get PRO
四月 '25
+5
在0个频道中
Get PRO
三月 '25
+17
在0个频道中
Get PRO
二月 '25
+12
在0个频道中
Get PRO
一月 '25
+18
在1个频道中
Get PRO
十二月 '24
+237
在0个频道中
Get PRO
十一月 '24
+1 122
在0个频道中
Get PRO
十月 '24
+1 120
在0个频道中
Get PRO
九月 '24
+1 527
在1个频道中
Get PRO
八月 '24
+1 128
在1个频道中
Get PRO
七月 '24
+1 216
在0个频道中
Get PRO
六月 '24
+781
在1个频道中
Get PRO
五月 '24
+797
在1个频道中
Get PRO
四月 '24
+808
在1个频道中
Get PRO
三月 '24
+821
在2个频道中
Get PRO
二月 '24
+753
在1个频道中
Get PRO
一月 '24
+768
在0个频道中
Get PRO
十二月 '23
+716
在1个频道中
Get PRO
十一月 '23
+96
在1个频道中
Get PRO
十月 '23
+86
在0个频道中
Get PRO
九月 '23
+73
在0个频道中
Get PRO
八月 '23
+90
在0个频道中
Get PRO
七月 '23
+107
在0个频道中
Get PRO
六月 '23
+105
在0个频道中
Get PRO
五月 '23
+169
在0个频道中
Get PRO
四月 '23
+128
在0个频道中
Get PRO
三月 '23
+84
在0个频道中
Get PRO
二月 '23
+75
在0个频道中
Get PRO
一月 '23
+71
在0个频道中
Get PRO
十二月 '22
+74
在0个频道中
Get PRO
十一月 '22
+149
在0个频道中
Get PRO
十月 '22
+90
在0个频道中
Get PRO
九月 '22
+138
在0个频道中
Get PRO
八月 '22
+77
在0个频道中
Get PRO
七月 '22
+50
在0个频道中
Get PRO
六月 '22
+96
在0个频道中
Get PRO
五月 '22
+75
在0个频道中
Get PRO
四月 '22
+80
在0个频道中
Get PRO
三月 '22
+65
在0个频道中
Get PRO
二月 '22
+26
在0个频道中
Get PRO
一月 '22
+56
在0个频道中
Get PRO
十二月 '21
+44
在0个频道中
Get PRO
十一月 '21
+39
在0个频道中
Get PRO
十月 '21
+61
在0个频道中
Get PRO
九月 '21
+66
在0个频道中
Get PRO
八月 '21
+65
在0个频道中
Get PRO
七月 '21
+96
在0个频道中
Get PRO
六月 '21
+120
在0个频道中
Get PRO
五月 '21
+130
在0个频道中
Get PRO
四月 '21
+812
在0个频道中
| 日期 | 订阅者增长 | 提及 | 频道 | |
| 06 十月 | +17 | |||
| 05 十月 | +7 | |||
| 04 十月 | +11 | |||
| 03 十月 | +5 | |||
| 02 十月 | +8 | |||
| 01 十月 | +2 |
频道帖子
Landmark Significance and Future Directions of the RAPID-TEST Trial
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854545
To the Editor The RAPID-TEST trial by Hay et al represents to our knowledge the first pragmatic randomized clinical trial to evaluate the use of multiplex molecular point-of-care testing (POCT) for respiratory tract infections in primary care. It establishes a rigorous evidence benchmark for the field. At the same time, its design limitations and evidence gaps provide a critical roadmap for future advancement.
| 2 | Expiration of Pandemic Food Assistance and Food Insufficiency in Adults With Disabilities
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854546
This cross-sectional study explores the prevalence of food insufficiency following the end of SNAP emergency allotments among adults with disabilities in 22 US states. | 376 |
| 3 | From Positive FIT Result to Colonoscopy—Closing a Gap in Care
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854548
Colorectal cancer screening is effective, yet underused. Fortunately, patients have a variety of options. They can select screening colonoscopy as the initial step, which offers the greatest sensitivity for advanced neoplasia, or take a 2-step approach that begins with a stool test. An advantage of the stool tests, such as the fecal immunochemical test (FIT), is that 9 out of 10 patients will have a negative test result and will not require a follow-up colonoscopy. | 333 |
| 4 | Low-Dose Rivaroxaban, Cardiovascular Events, and Kidney Disease—Reply
https://jamanetwork.com/journals/jama/fullarticle/2854849
In Reply TRACK was designed against a background of evidence that rivaroxaban at a dose far lower than required for therapeutic anticoagulation may provide cardiovascular protection with a favorable benefit-risk profile in advanced kidney disease. We agree with Dr Coppi that the results of our trial demonstrated that much of the cardiovascular disease in advanced kidney disease may not be atherothrombotic in nature and therefore may not be modifiable by atherothrombotic treatments. However, we do not concur with other assertions made by Dr Coppi. Patients with advanced kidney disease have been systematically excluded from cardiovascular outcome trials of antiplatelet agents. Observational studies have reported increased mortality with aspirin and clopidogrel use in patients receiving hemodialysis. Until dedicated cardiovascular outcome trials of antiplatelet agents in advanced kidney disease are completed and reported (eg, the Aspirin in Reducing Events in Dialysis [ASPIRED] trial), it is premature to assume that these therapies are safe or beneficial for broad cardiovascular risk reduction in this population. | 278 |
| 5 | Medicare and Bureau of Health Workforce and Funded Primary Care Residency Positions
https://jamanetwork.com/journals/jama/fullarticle/2854850
To the Editor We are writing about the Research Letter “Changes in Specialty and Geography of Medicare’s New Residency Positions,” which reported that Medicare-funded expansion has not substantially increased primary care or rural training capacity. However, we would like to highlight an important limitation of specialty-based workforce estimates: residency positions labeled as primary care may not accurately reflect the production of physicians who enter primary care practice. Because these estimates rely on specialty designation, they may overstate primary care workforce contributions and fail to capture graduates’ postresidency practice. | 214 |
| 6 | Low-Dose Rivaroxaban, Cardiovascular Events, and Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2854851
To the Editor I read with great interest the Treatment of Cardiovascular Disease With Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) trial and the insightful accompanying editorial regarding the use of low-dose rivaroxaban in patients with advanced chronic kidney disease (CKD). Although the investigators should be commended for undertaking this trial in a historically excluded population, the lack of cardiovascular efficacy and significant increase in major bleeding events highlight critical methodological limitations that warrant a strategic paradigm shift in future trial designs involving direct oral anticoagulants (DOACs) in end-stage kidney disease. | 203 |
| 7 | Opportunities and Challenges in Tobacco Treatment
https://jamanetwork.com/journals/jama/fullarticle/2854853
Evidence-based treatments and comprehensive tobacco control policies have driven a marked decline in cigarette smoking among US adults over time. Approximately 25 million adults in the US continue to smoke, a prevalence of 9.9%. The declines in cigarette smoking have not been evenly distributed, with higher smoking rates, reduced access to cessation support, and higher tobacco-related mortality among individuals with lower socioeconomic status, certain racial and ethnic minority populations, and those with mental health and/or substance use disorders. | 200 |
| 8 | Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854792
The open-label extension of the OPERA I and II randomized clinical trials assesses 10-year safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis. | 251 |
| 9 | Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854793
This randomized clinical trial evaluates whether earlier disclosure of plasma phosphorylated tau at threonine 217 and neurofilament light chain affects diagnostic certainty and clinical management. | 256 |
| 10 | Rapid Whole-Genome Sequencing in Pediatric Neurology Inpatients
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854794
This cohort study investigates the diagnostic yield and clinical impact of rapid whole-genome sequencing in pediatric neurology inpatients, and which clinical features are associated with a phenotype-concordant diagnosis. | 285 |
| 11 | Precision Care for Children With Neurologic Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854795
Diagnostic uncertainty hinders appropriate management, counseling, and holistic family care in children with pediatric neurological diseases. Whole-genome sequencing is now providing a new light in a dark tunnel for these children and their families. This is of greater relevance as genetic precision therapies, such as N-of-1 gene therapy programs, continue to emerge with efficacy greatest before irreversible neuronal injury. | 319 |
| 12 | Error in Figure
https://jamanetwork.com/journals/jamaneurology/fullarticle/2854796
The Research Letter titled “Temporal Patterns in Stroke Recurrence at Younger Ages: A Systematic Review and Meta-Analysis,” published online April 27, 2026, and in the June issue, had decimal errors in a portion of the y-axis labels in all 3 panels in the Figure. This article was corrected online. | 315 |
| 13 | Autism Incidence Has Remained Stable, Study Finds
https://jamanetwork.com/journals/jama/fullarticle/2854953
The incidence of autism spectrum disorder in South Korea remained stable across cohorts born from 1998 to 2010, according to a study published in JAMA Pediatrics. | 729 |
| 14 | Semaglutide Demonstrates Benefits Across Frailty Levels
https://jamanetwork.com/journals/jama/fullarticle/2854954
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology found. | 693 |
| 15 | PREVENT Equations Integrated Into Electronic Health Record Platform
https://jamanetwork.com/journals/jama/fullarticle/2854955
The American Heart Association (AHA) announced that its PREVENT equations are now integrated into Epic’s electronic health record platform. | 684 |
| 16 | JAMA Editors' Summary Podcast October 2, 2026
https://jamanetwork.com/journals/jama/fullarticle/2855018
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA. | 628 |
| 17 | Treating In-Hospital Cardiac Arrest With Sodium Bicarbonate—Reply
https://jamanetwork.com/journals/jama/fullarticle/2854748
In Reply In their letter about our recent BIHCA trial, Dr Gelbenegger and colleagues focus on the numerical differences in 30-day survival (12% vs 9.1%) and 30-day favorable neurological outcome (8.1% vs 5.4%) between groups. As noted, the trial was not powered for these outcomes and the results are uncertain. The 95% CIs for the risk ratio for 30-day survival ranged from 0.84 to 1.88 and for 30-day favorable neurological outcome from 0.82 to 2.34. As such, our results were compatible with harm, no effect, and benefit. Until well-conducted and sufficiently powered randomized clinical trials establish a benefit of sodium bicarbonate during cardiac arrest, consistent with international guidelines, we do not believe it should be administered routinely. | 725 |
| 18 | End-of-Life Care for People Who Are Incarcerated
https://jamanetwork.com/journals/jama/fullarticle/2854749
To the Editor Dr Mushero and colleagues highlight the need to improve hospice and end-of-life care for people who are incarcerated. For patients with advanced cancer, this discussion should explicitly include access to palliative radiotherapy. | 555 |
| 19 | Treating In-Hospital Cardiac Arrest With Sodium Bicarbonate
https://jamanetwork.com/journals/jama/fullarticle/2854750
To the Editor The Bicarbonate for In-Hospital Cardiac Arrest (BIHCA) trial demonstrated no significant improvement in return of spontaneous circulation with sodium bicarbonate administration, supporting current guidelines that do not recommend routine bicarbonate use during cardiac arrest. Nevertheless, several findings from the trial warrant further discussion. | 574 |
| 20 | Error in Results
https://jamanetwork.com/journals/jama/fullarticle/2854752
The Original Investigation titled “Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer: A Randomized Clinical Trial,” published on June 1, 2026, was corrected to fix typographical errors in the text, including indicating that the trial was stopped for futility at 75% information, rather than 78%, and the number of participants lost to follow-up in the nivolumab group in Figure 1. This article was corrected online. | 519 |
